Oncocross KRX:382150KOSDAQ
온코크로스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, Oncocross reported an operating loss of ₩2.7bn. Oncocross (온코크로스) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals 4 quarters of losses Screener
Oncocross quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | – | – | −₩2.7bn | ₩1.0bn |
| Q1 2026 | – | – | −₩2.5bn | −₩2.6bn |
| Q4 2025 derived | – | – | – | −₩2.9bn |
| Q3 2025 | ₩29m | -84.0% | −₩2.4bn | −₩2.0bn |
| Q2 2025 | ₩138m | -20.7% | −₩1.9bn | −₩1.8bn |
| Q1 2025 | ₩63m | +3.4% | −₩2.4bn | −₩2.3bn |
| Q4 2024 derived | ₩655m | +3413.2% | −₩2.4bn | −₩2.3bn |
| Q3 2024 | ₩183m | +823.6% | −₩1.5bn | −₩1.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Oncocross top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Oncocross news Korean headlines
No articles yet.